Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul-Dec;19(7-12):283-287.
doi: 10.1080/14789450.2023.2176757. Epub 2023 Feb 10.

Oncoproteomic profiling of AML: moving beyond genomics

Sunil K Joshi  1   2 , Cristina E Tognon  1   2 , Brian J Druker  1   2 , Karin D Rodland  1   3   4
Affiliations
Editorial

Oncoproteomic profiling of AML: moving beyond genomics

Sunil K Joshi et al. Expert Rev Proteomics. 2022 Jul-Dec.
No abstract available

Keywords: AML; FLT3 inhibitor; drug resistance; leukemia; oncoproteomics; phosphoproteomics; proteogenomics.

PubMed Disclaimer

Conflict of interest statement

B.J.Druker potential competing interests – Scientific advisory board: Adela Bio, Aileron Therapeutics, Therapy Architects/ALLCRON (inactive), Cepheid, Celgene, DNA SEQ, Nemucore Medical Innovations, Novartis, RUNX1 Research Program, Vivid Biosciences (inactive); scientific advisory board & Stock: Aptose Biosciences, Blueprint Medicines, Enliven Therapeutics, Iterion Therapeutics, GRAIL, Recludix Pharma; Board of Directors & Stock: Amgen, Vincerx Pharma; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Advisory Committee: Multicancer Early Detection Consortium; Founder: VB Therapeutics; Sponsored Research Agreement: Enliven Therapeutics, Recludix Pharma; Clinical Trial Funding: Novartis, Astra-Zeneca; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license, one CytoImage, Inc. exclusive license, and one Sun Pharma Advanced Research Company non-exclusive license); US Patents 4326534, 6958335, 7416873, 7592142, 10473667, 10664967, 11049247.

C.E.Tognon potential competing interests – scientific advisory board: Notable Labs. Sponsored research: Notable Labs. Consultant: St. Jude’s Children’s Hospital.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1.
Figure 1.. Proteomics & phosphoproteomics can unveil the dynamic nature of AML.
a. An integrative approach that combined genomic, metabolomic, phosphoproteomic, proteomic analyses with small-molecule inhibitor and genome-wide CRISPR screens revealed a stepwise process for FLT3 inhibitor resistance. This discovery dataset led to the creation of a targeted proteomics panel that was used to investigate FLT3 inhibitor resistance in a subset of ex vivo serial patient samples. Our cell culture model recapitulated the underlying biology of patients resistant to FLT3 inhibitors. b. The integration and aggregation of the amassing - omics data with ex vivo small-molecule inhibitor screening holds the potential to individualize clinical management for patients with cancer.
See this image and copyright information in PMC

References

    1. Shruthi BS, Selvamani Vinodhkumar P., proteomics: a new perspective for cancer. Adv Biomed Res. 2016;5(p. 67):. - PMC - PubMed
    1. Kwon YW, Jo HS, Bae S, et al. Application of proteomics in cancer: recent trends and approaches for biomarkers discovery. Front Med (Lausanne). 2021;8(p. 747333). - PMC - PubMed
    1. Mani DR, Krug K, Zhang B, et al. Cancer proteogenomics: current impact and future prospects. Nat Rev Cancer. 2022;22(5):298–313. - PubMed

    2. • Excellent review that reveals how proteomics and phosphoproteomics provide an additional layer to understanding cancer biology.

    1. Casado P, Wilkes EH, Miraki-Moud F, et al. Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. Leukemia. 2018;32 (8):1818–1822. - PMC - PubMed

    2. •• First study to profile primary AML cells through an integrated omics approach that includes proteomics and phosphoproteomics.

    1. de Boer B, Prick J, Pruis MG, et al. Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell. 2018;34(4):674–689. e8. - PubMed

Publication types

Substances

LinkOut - more resources